Whitehawk Therapeutics publishes HWK-016 preclinical presentation on MUC16-targeting ADC

• Whitehawk Therapeutics published preclinical data for HWK-016, a MUC16-targeting antibody-drug conjugate designed to bind non-shed MUC16 extracellular domain rather than circulating CA125.
• In cell assays, exogenous CA125 at 10,623 U/mL shifted HWK-016 antibody binding EC50 3-fold to 0.67 nM from 0.22 nM.
• In an ovarian cancer OVCAR-3 xenograft model, HWK-016 produced 108% tumor growth inhibition at 6 mg/kg with 4 complete responses out of 7 animals.
• Repeat-dose toxicology in cynomolgus monkeys showed highest non-severely toxic dose of 60 mg/kg with no mortalities reported.
• Whitehawk said HWK-016 is being evaluated in a Phase 1 study in advanced ovarian or endometrial cancers (NCT07470853).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on April 19, 2026, and is solely responsible for the information contained therein.